منابع مشابه
Bosutinib for Chronic Myeloid Leukemia
In recent years the availability of several tyrosine kinase inhibitors (TKI) in the therapeutic armamentarium for chronic myeloid leukemia has dramatically changed the objectives and expectations of healthcare providers and patients. For many, but not all, patients the forerunner of TKI, imatinib, is still an excellent treatment option. Unfortunately, nearly 30-40% of imatinib-treated patients ...
متن کاملAllografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
The current treatment of chronic phase chronic myeloid leukemia (CML) consists of oral tyrosine kinase inhibitors (TKIs). However, high-risk CML may present with an aggressive course which may result in blastic crisis or a "difficult-to-manage" state with available treatments. The aim of this paper is to report a patient with complicated CML resistant to treatment and progressed despite the adm...
متن کاملBosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
Bosutinib is one of five tyrosine kinase inhibitors commercially available in the United States for the treatment of chronic myeloid leukemia. This review of bosutinib summarizes the mode of action, pharmacokinetics, efficacy and safety data, as well as the patient-focused perspective through quality-of-life data. Bosutinib has shown considerable and sustained efficacy in chronic myeloid leukem...
متن کاملBosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects
The past decade has witnessed great advances in the treatment of chronic myeloid leukemia (CML), brought about in large part by the development of BCR-ABL tyrosine kinase inhibitors (TKIs). Bosutinib joins the armamentarium of approved TKIs for the treatment of chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome (Ph)-positive CML resistant to or intolerant o...
متن کاملBTT-30182-bosutinib-in-the-management-of-chronic-myeloid-leukemia-; published by Dove Press
Correspondence: Gunhild Keller-von Amsberg Klinik für Hämatologie und Onkologie mit der Sektion Pneumologie, Onkologisches Zentrum, Universitäts-Klinikum Hamburg-Eppendorf, Martinistraβe 52, 20246 Hamburg, Germany Tel +49 40 74105 3962 Fax +49 40 74105 8054 Email [email protected] Abstract: Bosutinib (SKI-606) is an orally available, once-daily dual Src and Abl kinase inhibitor, approved by ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rare Cancers and Therapy
سال: 2015
ISSN: 2195-6014,2195-6022
DOI: 10.1007/s40487-015-0010-y